U. Vehling-Kaiser

CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial)

Marlies Michl, Sebastian Stintzing, Ludwig Fischer von Weikersthal et al. · Annals of Oncology · 2016 · 42 citations

Medicine, Oncology, Pharmacology +16

Long-term outcome of hairy cell leukemia treated with 2-chlorodeoxyadenosine

U. Jehn, Reiner Bartl, Hermann Dietzfelbinger et al. · Annals of Hematology · 1999 · 30 citations

Medicine, Hematology, Oncology +12

Gemcitabine and Carboplatin in Intensively Pretreated Patients with Metastatic Breast Cancer

D. Laessig, Hans‐Joachim Stemmler, U. Vehling-Kaiser et al. · Oncology · 2007 · 27 citations · Full text

Medicine, Oncology, Pharmacology +17

Nutrition care in patients with cancer: A retrospective multicenter analysis of current practice – Indications for further studies?

M. Drissi, O. Cwieluch, P. Lechner et al. · Clinical Nutrition · 2014 · 17 citations

Agriculture, Nutrition, Oncology +17

Gemcitabine plus erlotinib (GE) followed by capecitabine (C) versus capecitabine plus erlotinib (CE) followed by gemcitabine (G) in advanced pancreatic cancer (APC): A randomized, cross-over phase III trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

Stefan Boeck, U. Vehling-Kaiser, Dirk Waldschmidt et al. · Journal of Clinical Oncology · 2010 · 17 citations

Medicine, Oncology, Pharmacology +12